These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 29604399)
41. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564 [TBL] [Abstract][Full Text] [Related]
42. Construction of a reference material panel for detecting Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175 [TBL] [Abstract][Full Text] [Related]
43. Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. Preusser M; Berghoff AS; Koller R; Zielinski CC; Hainfellner JA; Liebmann-Reindl S; Popitsch N; Geier CB; Streubel B; Birner P Eur J Cancer; 2015 Sep; 51(13):1803-11. PubMed ID: 26164066 [TBL] [Abstract][Full Text] [Related]
44. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation. Tanizaki J; Banno E; Togashi Y; Hayashi H; Sakai K; Takeda M; Kaneda H; Nishio K; Nakagawa K Lung Cancer; 2016 Nov; 101():11-15. PubMed ID: 27794398 [TBL] [Abstract][Full Text] [Related]
45. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis. Li WY; Zhao TT; Xu HM; Wang ZN; Xu YY; Han Y; Song YX; Wu JH; Xu H; Yin SC; Liu XY; Miao ZF BMC Cancer; 2019 Feb; 19(1):145. PubMed ID: 30760227 [TBL] [Abstract][Full Text] [Related]
46. Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations. Kauffmann-Guerrero D; Tufman A; Kahnert K; Bollmann BA; Reu S; Syunyaeva Z; Schneider C; Manapov F; Huber RM; Golpon H Oncol Res Treat; 2020; 43(6):289-298. PubMed ID: 32268332 [TBL] [Abstract][Full Text] [Related]
48. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples. Ma C; Yang X; Xing W; Yu H; Si T; Guo Z Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608 [TBL] [Abstract][Full Text] [Related]
49. Mutation Status of Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662 [TBL] [Abstract][Full Text] [Related]
50. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352 [TBL] [Abstract][Full Text] [Related]
52. Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis. Yan W; Liu Y; Li J; Han A; Kong L; Yu J; Zhu H Radiat Oncol; 2019 Sep; 14(1):168. PubMed ID: 31521171 [TBL] [Abstract][Full Text] [Related]
53. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250 [TBL] [Abstract][Full Text] [Related]
54. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways. Scheffler M; Ihle MA; Hein R; Merkelbach-Bruse S; Scheel AH; Siemanowski J; Brägelmann J; Kron A; Abedpour N; Ueckeroth F; Schüller M; Koleczko S; Michels S; Fassunke J; Pasternack H; Heydt C; Serke M; Fischer R; Schulte W; Gerigk U; Nogova L; Ko YD; Abdulla DSY; Riedel R; Kambartel KO; Lorenz J; Sauerland I; Randerath W; Kaminsky B; Hagmeyer L; Grohé C; Eisert A; Frank R; Gogl L; Schaepers C; Holzem A; Hellmich M; Thomas RK; Peifer M; Sos ML; Büttner R; Wolf J J Thorac Oncol; 2019 Apr; 14(4):606-616. PubMed ID: 30605727 [TBL] [Abstract][Full Text] [Related]
55. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients. Das BR; Bhaumik S; Ahmad F; Mandsaurwala A; Satam H Pathol Oncol Res; 2015 Jul; 21(3):675-87. PubMed ID: 25637496 [TBL] [Abstract][Full Text] [Related]
56. Colorectal cancer metastatic to the brain: analysis of prognostic factors and impact of KRAS mutations on presentation and outcome. Nieder C; Hintz M; Grosu AL Clin Transl Oncol; 2016 Jan; 18(1):88-92. PubMed ID: 26260912 [TBL] [Abstract][Full Text] [Related]
57. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627 [TBL] [Abstract][Full Text] [Related]
58. Epidermal growth factor receptor mutations should be considered as a prognostic factor for survival of patients with pathological fractures or painful bone metastases from non-small cell lung cancer. Willeumier JJ; van der Hoeven NM; Bollen L; Willems LN; Fiocco M; van der Linden YM; Dijkstra PD Bone Joint J; 2017 Apr; 99-B(4):516-521. PubMed ID: 28385942 [TBL] [Abstract][Full Text] [Related]
59. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients. Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754 [TBL] [Abstract][Full Text] [Related]
60. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy. Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]